Sign in

CIK 0001664710

  • Non-accelerated filer
  • Smaller reporting company

Keros Therapeutics, Inc.

Sign in to watch
Ticker
KROS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
811173868
Phone
+1 617-314-6297
Business address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$5,619
in 1 filing, $6K under 10b5-1 plans

Net −$5,619. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Prener Anne −$6K Director sold 4% of stake
Date Insider Transaction Shares Price Value Owned after
2020-04-13 Arkin Bio Ventures Limited Partnership 10% owner Conversion · Series B-1 Preferred Stock −343,270 0
2020-04-13 Arkin Bio Ventures Limited Partnership 10% owner Conversion · Series C Preferred Stock −167,537 0
2020-04-07 Seehra Jasbir Chief Executive Officer Grant or award · Employee Stock Option (right to buy) +696,569 696,569
2020-04-07 Regnante Keith Chief Financial Officer Grant or award · Employee Stock Option (right to buy) +18,430 18,430
2020-04-07 Regnante Keith Chief Financial Officer Grant or award · Employee Stock Option (right to buy) +133,622 133,622
2020-04-07 Ordonez Claudia Chief Medical Officer Grant or award · Employee Stock Option (right to buy) +18,430 18,430
2020-04-07 Lachey Jennifer Chief Scientific Officer Grant or award · Employee Stock Option (right to buy) +241,222 241,222

Page 36 of 36 · 707 trades